LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2023

October 25, 2023 | Last Trade: US$22.81 0.11 -0.48

BANNOCKBURN, Ill., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2023.

Third Quarter 2023 Financial Results and Highlights

  • Net revenue of $1,093.0 million, up 7.1% compared to $1,020.9 million in the third quarter of 2022
  • Gross profit of $254.3 million, or 23.3% of net revenue, up 16.6% compared to $218.0 million, or 21.4% of net revenue, in the third quarter of 2022
  • Net income of $56.3 million, or $0.31 basic earnings per share, up 45.0% compared to net income of $38.8 million, or $0.21 basic earnings per share, in the third quarter of 2022
  • Adjusted EBITDA of $109.8 million, up 28.2% compared to $85.6 million in the third quarter of 2022
  • Cash flow from operations of $61.0 million compared to $87.0 million in the third quarter of 2022
  • Cash and cash equivalents balance was $386.5 million at the end of the third quarter of 2023

John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team continues to execute on outstanding clinical outcomes and extraordinary patient care, which helped translate into solid financial results in the third quarter. I am excited to build on this momentum as we close out the year and look forward to seeing the impact we believe the team will make in the post-acute and ambulatory setting in the years to come.”

Updated Full Year 2023 Financial Guidance

For the full year 2023, Option Care Health expects to generate:

  • Net revenue of $4.23 billion to $4.28 billion
  • Adjusted EBITDA of $420 million to $425 million
  • Cash flow from operations of at least $350 million, inclusive of the Amedisys merger termination fee net of merger-related expenses

Additionally, the Company anticipates an effective tax rate of approximately 27% and net interest expense of approximately $52.0 million to $54.0 million.

Conference Call

Option Care Health will host a conference call to discuss its third quarter 2023 financial results later today at 8:30 a.m. EDT. The conference call can be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

Investor Contacts

Mike ShapiroBob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial OfficerWestwicke
T: (312) 940-2538T: (413) 213-0500
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

 Schedule 1

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
 
 September 30, 2023 December 31, 2022
ASSETS   
CURRENT ASSETS:   
Cash and cash equivalents$386,489 $294,186
Accounts receivable, net 382,957  377,542
Inventories 251,366  224,281
Prepaid expenses and other current assets 95,473  98,330
Total current assets 1,116,285  994,339
    
NONCURRENT ASSETS:   
Property and equipment, net 107,960  108,321
Intangible assets, net 20,868  22,371
Referral sources, net 323,126  341,744
Goodwill 1,540,246  1,533,424
Other noncurrent assets 135,131  112,737
Total noncurrent assets 2,127,331  2,118,597
TOTAL ASSETS$3,243,616 $3,112,936
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
CURRENT LIABILITIES:   
Accounts payable$429,536 $378,763
Other current liabilities 194,548  186,588
Total current liabilities 624,084  565,351
    
NONCURRENT LIABILITIES:   
Long-term debt, net of discount, deferred financing costs and current portion 1,057,016  1,058,204
Other noncurrent liabilities 122,433  103,278
Total noncurrent liabilities 1,179,449  1,161,482
Total liabilities 1,803,533  1,726,833
    
STOCKHOLDERS’ EQUITY 1,440,083  1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,243,616 $3,112,936

Schedule 2

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
 
 Three Months Ended September 30, Nine Months Ended September 30,
  2023   2022   2023   2022 
NET REVENUE$1,093,014  $1,020,918  $3,177,934  $2,917,522 
COST OF REVENUE 838,748   802,917   2,443,834   2,281,685 
GROSS PROFIT 254,266   218,001   734,100   635,837 
        
OPERATING COSTS AND EXPENSES:       
Selling, general and administrative expenses 158,214   142,015   459,644   417,771 
Depreciation and amortization expense 15,005   15,268   44,417   46,027 
Total operating expenses 173,219   157,283   504,061   463,798 
OPERATING INCOME 81,047   60,718   230,039   172,039 
        
OTHER INCOME (EXPENSE):       
Interest expense, net (11,786)  (13,997)  (38,816)  (39,008)
Other, net 824   5,360   88,594   7,956 
Total other (expense) income (10,962)  (8,637)  49,778   (31,052)
        
INCOME BEFORE INCOME TAXES 70,085   52,081   279,817   140,987 
INCOME TAX EXPENSE 13,783   13,258   69,904   37,960 
NET INCOME$56,302  $38,823  $209,913  $103,027 
        
Earnings per share, basic$0.31  $0.21  $1.17  $0.57 
Earnings per share, diluted$0.31  $0.21  $1.16  $0.57 
        
Weighted average common shares outstanding, basic 178,826   181,884   179,956   180,829 
Weighted average common shares outstanding, diluted 180,528   183,022   181,286   181,760 

Schedule 3

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
 
 Nine Months Ended September 30,
  2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:   
Net income$209,913  $103,027 
Adjustments to reconcile net income to net cash provided by operations:   
Depreciation and amortization expense 46,423   49,723 
Other non-cash adjustments 54,259   66,999 
Changes in operating assets and liabilities:   
Accounts receivable, net (5,075)  (23,153)
Inventories (28,362)  (52,749)
Accounts payable 50,726   129,859 
Other (7,558)  (49,614)
Net cash provided by operating activities 320,326   224,092 
    
CASH FLOWS FROM INVESTING ACTIVITIES:   
Acquisition of property and equipment (21,981)  (17,111)
Business acquisitions, net of cash acquired (12,855)  (87,315)
Other investing activities (5,889)   
Net cash used in investing activities (40,725)  (104,426)
    
CASH FLOWS FROM FINANCING ACTIVITIES:   
Purchase of company stock (175,108)   
Proceeds from warrant exercises    20,916 
Other financing cash flows (12,190)  (4,537)
Net cash (used in) provided by financing activities (187,298)  16,379 
NET INCREASE IN CASH AND CASH EQUIVALENTS 92,303   136,045 
Cash and cash equivalents - beginning of the period 294,186   119,423 
CASH AND CASH EQUIVALENTS - END OF PERIOD$386,489  $255,468 

Schedule 4

OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)
 
 Three Months Ended September 30, Nine Months Ended September 30,
  2023  2022   2023   2022
Net income$56,302 $38,823  $209,913  $103,027
Interest expense, net 11,786  13,997   38,816   39,008
Income tax expense 13,783  13,258   69,904   37,960
Depreciation and amortization expense 15,622  16,474   46,423   49,723
EBITDA 97,493  82,552   365,056   229,718
        
EBITDA adjustments       
Stock-based incentive compensation 9,235  4,005   22,908   12,581
Restructuring, acquisition, integration and other (1) 3,029  (934)  (74,383)  6,282
Adjusted EBITDA$109,757 $85,623  $313,581  $248,581

(1) Restructuring, acquisition, integration and other for the nine months ended September 30, 2023 includes the Amedisys merger termination fee, net of merger-related expenses

Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB